Plasma Fractionation Market by Product (Albumin, Immunoglobulin, Coagulation Factor VIII and Coagulation Factor IX), Sector (Public Sector and Private Sector): Global Opportunity Analysis and Industry Forecast, 20202027
- Published Date: 2020-11-26
- Report ID: 21709
- Pages: 208
-
Format:
The global plasma fractionation market accounted for $18,222 million in 2019, and is expected to reach $23,006 million by 2027, registering a CAGR of 6.2% from 2020 to 2027.
Fractionation is a mechanical process carried out to separate a certain quantity of mixture. Plasma is the liquid part of blood which is yellowish and holds blood cells. Plasma fractionation is carried out to separate high quality, proteinaceous products such as albumin and immunoglobulins. These derived products are known as plasma derivatives obtained from fractionation. Moreover, these products are used in various medical fields such as in neurology, hematology, critical care, and immunology. For instance, in critical care, plasma is prescribed to prevent and stop bleeding. In addition, plasma products are widely used in clinical research laboratories and hospitals. In addition, there are majorly two types of players that conduct plasma fractionation such as public players and private players. Moreover, public players include the companies which are non-profit government run bodies that fractionate plasma. Similarly, private players include the companies which earn profit by the sale of fractionated plasma products.
Surge in geriatric population across the globe, which is predisposed to various rare diseases that require use of plasma derivatives is the major factor that boosts the market growth. Moreover, rise in use of immunoglobulins and alpha-1-antitrypsin in areas of medicine worldwide also fuels growth of the plasma fractionation market. Furthermore, surge in plasma collection centers worldwide is another major factor that contributes toward growth of this market.
In addition, favorable government support to spread awareness related to use of plasma derived products also fuels growth of the plasma fractionation market. However, fractionation is an expensive procedure, which includes collection of pooled blood from a large group of individuals. These individuals undergo screening to detect and avoid diseases, which can be transmitted through plasma. Furthermore, plasma-derived products are further screened post formulation to destroy any bacteria and viruses present in the product. These steps, in turn, make plasma derived products expensive which serves as a hindrance to the growth of the market. Conversely, growth potential in emerging economies is expected to create lucrative opportunities for the market growth during the forecast period. Furthermore, there are advancements in processes, improved formulations, and increase in production efficiency. Advancement in technology leads to improved process of plasma manufacturing, hence leading to growth of the market
The global plasma fractionation market is segmented on the basis of product, sector, and country. On the basis of product, the market is divided into albumin, immunoglobulins, coagulation factor VIII, and coagulation factor IX. By sector, the market is classified into public sector and private sector. By country, it is analyzed across Turkey, Russia, Korea, Kingdom of Saudi Arabia, Taiwan, Indonesia, Thailand, Malaysia, Canada, Vietnam and rest of the world.
The global plasma fractionation market is highly competitive and the prominent players in the market have adopted various strategies to garner maximum plasma fractionation market share. These include collaboration, product launch, partnership, and acquisition. Major players operating in the market include Grifols SA, Baxter International Inc, CSL LTD., Bio Product Laboratory, Octapharma AG, Sanquin, Laboratoire Franais Du Fractionnement Et Des Biotechnologies, Kedrion, Biotest, and Takeda Pharmaceuticals.
KEY BENEFITS FOR STAKEHOLDERS
This report entails a detailed quantitative analysis along with the current global plasma fractionation market trends from 2019 to 2027 to identify the prevailing opportunities along with the strategic assessments.
The market size and estimations are based on a comprehensive analysis of key developments in the industry.
A qualitative analysis based on innovative products facilitates strategic business planning.
The development strategies adopted by the key market players are enlisted to understand the competitive scenario of the market
Key Market Segments
By Product
o Albumin
o Immunoglobulin
o Coagulation Factor VIII
o Coagulation Factor IX
By Sector
o Public Sector
o Private Sector
By Country
o Turkey
o Russia
o South Korea
o Saudi Arabia
o Taiwan
o Indonesia
o Thailand
o Malaysia
o Canada
o Vietnam
o Rest of the World
List of key players profiled in the report:
Grifols SA
Baxter International Inc
CSL LTD.
Bio Product Laboratory
Octapharma AG
Sanquin
Laboratoire Franais Du Fractionnement Et Des Biotechnologies
Kedrion
Biotest
Takeda Pharmaceuticals
LIST OF OTHER PLAYERS IN THE VALUE CHAIN(These players are not profiled in the report. The same will be included on request)
China Biologic Products
China Biologic Products.
CHAPTER 1:INTRODUCTION
1.1.Report description
1.2.Key benefits for stakeholders
1.3.Key market segments
1.3.1.List of key players profiled in the report
1.4.Research methodology
1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools and models
CHAPTER 2:EXECUTIVE SUMMARY
2.1.Key findings of the study
2.2.CXO perspective
CHAPTER 3:MARKET OVERVIEW
3.1.Market definition and scope
3.2.Key findings
3.2.1.Top investment pockets
3.3.Porter's five forces analysis
3.3.1.Bargaining power of buyers
3.3.2.Bargaining power of suppliers
3.3.3.Thereat of new entrants
3.3.4.Threat of substitutes
3.3.5.Intensity of competitive rivalry
3.4.Top player positioning, 2019
3.5.Market dynamics
3.5.1.Drivers
3.5.1.1.Surge in geriatric population across, coupled with rise in prevalence of rare diseases
3.5.1.2.Rise in use of immunoglobulins in medicine
3.5.1.3.Increase in number of plasma collection centers across the globe
3.5.2.Restraint
3.5.2.1.High cost of plasma derived products
3.5.3.Opportunity
3.5.3.1.High growth potential in emerging economies
3.5.4.Impact Analysis
CHAPTER 4:PLASMA FRACTIONATION MARKET, BY PRODUCT
4.1.Overview
4.1.1.Market size and forecast
4.2.Albumin
4.2.1.Key market trends and growth opportunities
4.2.2.Market size and forecast, by country
4.3.Immunoglobulins
4.3.1.Key market trends and growth opportunities
4.3.2.Market size and forecast, by country
4.4.Coagulation factor VIII
4.4.1.Key market trends and growth opportunities
4.4.2.Market size and forecast, by country
4.5.Coagulation factor IX
4.5.1.Key market trends and growth opportunities
4.5.2.Market size and forecast, by country
CHAPTER 5:PLASMA FRACTIONATION MARKET, BY SECTOR
5.1.Overview
5.1.1.Market size and forecast
5.2.Public Sector
5.2.1.Market size and forecast, by region
5.3.Private Sector
5.3.1.Market size and forecast, by country
CHAPTER 6:PLASMA FRACTIONATION MARKET, BY COUNTRY
6.1.Overview
6.1.1.Market size and forecast
6.2.Turkey
6.2.1.Key market trends and growth opportunities
6.2.2.Market size and forecast, by product
6.2.3.Market size and forecast, by sector
6.3.Russia
6.3.1.Key market trends and growth opportunities
6.3.2.Market size and forecast, by product
6.3.3.Market size and forecast, by sector
6.4.Korea (South Korea)
6.4.1.Key market trends and growth opportunities
6.4.2.Market size and forecast, by product
6.4.3.Market size and forecast, by sector
6.5.Kingdom of Saudi Arabia
6.5.1.Key market trends and growth opportunities
6.5.2.Market size and forecast, by product
6.5.3.Market size and forecast, by sector
6.6.Taiwan
6.6.1.Key market trends and growth opportunities
6.6.2.Market size and forecast, by product
6.6.3.Market size and forecast, by sector
6.7.Indonesia
6.7.1.Key market trends and growth opportunities
6.7.2.Market size and forecast, by product
6.7.3.Market size and forecast, by sector
6.8.Thailand
6.8.1.Key market trends and growth opportunities
6.8.2.Market size and forecast, by product
6.8.3.Market size and forecast, by sector
6.9.Malaysia
6.9.1.Key market trends and growth opportunities
6.9.2.Market size and forecast, by product
6.9.3.Market size and forecast, by sector
6.10.Canada
6.10.1.Key market trends and growth opportunities
6.10.2.Market size and forecast, by product
6.10.3.Market size and forecast, by sector
6.11.Vietnam
6.11.1.Key market trends and growth opportunities
6.11.2.Market size and forecast, by product
6.11.3.Market size and forecast, by sector
6.12.Rest of the World
6.12.1.Key market trends and growth opportunities
6.12.2.Market size and forecast, by product
6.12.3.Market size and forecast, by sector
CHAPTER 7:COMPANY PROFILES
7.1.BAXTER INTERNATIONAL INC.
7.1.1.Company overview
7.1.2.Company snapshot
7.1.3.Operating business segments
7.1.4.Product portfolio
7.1.5.Business performance
7.2.BIO PRODUCTS LABORATORY
7.2.1.Company overview
7.2.2.Company snapshot
7.2.3.Operating business segments
7.2.4.Product portfolio
7.2.5.Key strategic moves and developments
7.3.BIOTEST AG
7.3.1.Company overview
7.3.2.Company snapshot
7.3.3.Operating business segments
7.3.4.Product portfolio
7.3.5.Business performance
7.3.6.Key strategic moves and developments
7.4.CSL LTD.
7.4.1.Company overview
7.4.2.Company snapshot
7.4.3.Operating business segments
7.4.4.Product portfolio
7.4.5.Business performance
7.4.6.Key strategic moves and developments
7.5.GRIFOLS SA
7.5.1.Company overview
7.5.2.Company snapshot
7.5.3.Operating business segments
7.5.4.Product portfolio
7.5.5.Business performance
7.5.6.Key strategic moves and developments
7.6.KEDRION S.P.A. (KEDRION BIOPHARMA INC.)
7.6.1.Company overview
7.6.2.Company snapshot
7.6.3.Operating business segments
7.6.4.Product portfolio
7.6.5.Business performance
7.7.LFB S. A
7.7.1.Company overview
7.7.2.Company snapshot
7.7.3.Operating business segments
7.7.4.Product portfolio
7.8.OCTAPHARMA AG
7.8.1.Company overview
7.8.2.Company snapshot
7.8.3.Operating business segments
7.8.4.Product portfolio
7.8.5.Business performance
7.8.6.Key strategic moves and developments
7.9.SANQUIN BLOOD SUPPLY FOUNDATION
7.9.1.Company overview
7.9.2.Company snapshot
7.9.3.Operating business segments
7.9.4.Product portfolio
7.9.5.Business performance
7.9.6.Key strategic moves and developments
7.10.TAKEDA PHARMACEUTICAL COMPANY LIMITED
7.10.1.Company overview
7.10.2.Company snapshot
7.10.3.Operating business segments
7.10.4.Product portfolio
7.10.5.Business performance
7.10.6.Key strategic moves and developments
Call Us
( India toll free )
+91 835 605 0278
( US toll free )
+1 800 601 6071
Drop us an email at
sales@prudentmarkets.com
Get your pre and post sales queries resolved by our Subject matter experts.
We will assist you to customize the report to fit your research needs.
Our prime focus is to provide qualitative and accurate data.
Feel free to order a sample report before purchase.
Your personal and confidential information is safe and secured.
